Cargando…

Immune dysregulation in myelodysplastic syndrome

Myelodysplastic syndrome (MDS) represents one of the most challenging health-related problems in the elderly. Characterized by dysplastic morphology in the bone marrow in association with ineffective hematopoiesis, pathophysiological causes of this disease are diverse including genetic abnormalities...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimori, Chiharu, List, Alan F., Epling-Burnette, Pearlie K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222262/ https://www.ncbi.nlm.nih.gov/pubmed/22184512 http://dx.doi.org/10.4081/hr.2010.e1

Ejemplares similares

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes
por: Mailloux, Adam W., et al.
Publicado: (2013)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
por: Sharma, Vasundhara, et al.
Publicado: (2020)

Role of Polyamines in Immune Cell Functions
por: Hesterberg, Rebecca S., et al.
Publicado: (2018)

Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes
por: Dong, Wen, et al.
Publicado: (2016)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
por: Yang, Lili, et al.
Publicado: (2012)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
por: Zhang, Xiaoying, et al.
Publicado: (2023)

MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells
por: Dong, Wen, et al.
Publicado: (2016)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
por: Comont, Thibault, et al.
Publicado: (2021)

Mesenchymal Cell Reprogramming in Experimental MPL(W515L) Mouse Model of Myelofibrosis
por: Han, Ying, et al.
Publicado: (2017)

Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
por: Park, Hee Sue, et al.
Publicado: (2017)

Bone Marrow Mononuclear Cells Up-Regulate Toll-Like Receptor Expression and Produce Inflammatory Mediators in Response to Cigarette Smoke Extract
por: Zhou, Junmin, et al.
Publicado: (2011)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation
por: Park, Derek S., et al.
Publicado: (2019)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Angiogenesis in myelodysplastic syndromes
por: Pruneri, G, et al.
Publicado: (1999)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
por: Chokr, Nora, et al.
Publicado: (2018)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma
por: Rollison, Dana E., et al.
Publicado: (2021)

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
por: Kittang, Astrid Olsnes, et al.
Publicado: (2016)

Immune dysregulation in Down syndrome
por: Bordon, Yvonne
Publicado: (2023)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

MicroRNAs in the Myelodysplastic Syndrome
por: Veryaskina, Y. A., et al.
Publicado: (2021)

Myelodysplastic Syndrome Associated With Auto-Immune Inflammatory Disease in VEXAS Syndrome
por: Thomas, Vibha Taneja, et al.
Publicado: (2021)

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
por: Sallman, David A., et al.
Publicado: (2022)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Preclinical modeling of myelodysplastic syndromes
por: Rouault-Pierre, K, et al.
Publicado: (2017)

Metchnikoff’s legacy: the dysplastic nature of innate immunity in myelodysplastic syndromes
por: Greenberg, Peter L.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u4u117tnar866fd0prvhcbf2qh